Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    January 2022
  1. PARK J, Yoon H, Shin CM, Park YS, et al
    Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study.
    PLoS One. 2022;17:e0262571.
    PubMed     Abstract available


  2. BAKER KA, Miller TD, Marino FE, Hartmann TE, et al
    The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262534.
    PubMed     Abstract available


  3. LAI HC, Chou JW, Wu YH, Huang PJ, et al
    ABO blood type and clinical characteristics of patients with ulcerative colitis: A hospital-based study in central Taiwan.
    PLoS One. 2022;17:e0260018.
    PubMed     Abstract available


  4. XU F, Wheaton AG, Liu Y, Greenlund KJ, et al
    Major ambulatory surgery among US adults with inflammatory bowel disease, 2017.
    PLoS One. 2022;17:e0264372.
    PubMed     Abstract available


  5. GARDINER LJ, Carrieri AP, Bingham K, Macluskie G, et al
    Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.
    PLoS One. 2022;17:e0263248.
    PubMed     Abstract available


  6. TONG G, Qian H, Li D, Li J, et al
    Establishment and evaluation of a specific antibiotic-induced inflammatory bowel disease model in rats.
    PLoS One. 2022;17:e0264194.
    PubMed     Abstract available


  7. SAETERSTAD S, Ostvik AE, Royset ES, Bakke I, et al
    Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn's disease.
    PLoS One. 2022;17:e0265189.
    PubMed     Abstract available


  8. YAO J, Fekadu G, Jiang X, You JHS, et al
    Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic-A cost-effectiveness analysis.
    PLoS One. 2022;17:e0266464.
    PubMed     Abstract available


  9. LEE SH, Veeriah V, Levine F
    A potent HNF4alpha agonist reveals that HNF4alpha controls genes important in inflammatory bowel disease and Paneth cells.
    PLoS One. 2022;17:e0266066.
    PubMed     Abstract available


  10. NGUYEN TB, Do DN, Nguyen TTP, Nguyen TL, et al
    Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.
    PLoS One. 2022;17:e0267358.
    PubMed     Abstract available


  11. WAKAI M, Hayashi R, Ueno Y, Onishi K, et al
    Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.
    PLoS One. 2022;17:e0264836.
    PubMed     Abstract available


  12. SHEU NW, Huang SH, Wu DC, Kao JY, et al
    Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus.
    PLoS One. 2022;17:e0265323.
    PubMed     Abstract available


  13. WEDENOJA S, Saarikivi A, Malkonen J, Leskinen S, et al
    Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease.
    PLoS One. 2022;17:e0269561.
    PubMed     Abstract available


  14. HIGUCHI N, Hiraga H, Sasaki Y, Hiraga N, et al
    Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50.
    PLoS One. 2022;17:e0269728.
    PubMed     Abstract available


  15. WANG J, Kou F, Han X, Shi L, et al
    Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.
    PLoS One. 2022;17:e0270297.
    PubMed     Abstract available


  16. OZAKA S, Sonoda A, Ariki S, Minata M, et al
    Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice.
    PLoS One. 2022;17:e0269698.
    PubMed     Abstract available


  17. DAS B, Rabalais J, Kozan P, Lu T, et al
    The effect of a fennel seed extract on the STAT signaling and intestinal barrier function.
    PLoS One. 2022;17:e0271045.
    PubMed     Abstract available


  18. HANSEN TM, Nugent Z, Bernstein CN, Samadder NJ, et al
    Characteristics of colorectal cancer and use of colonoscopy before colorectal cancer diagnosis among individuals with inflammatory bowel disease: A population-based study.
    PLoS One. 2022;17:e0272158.
    PubMed     Abstract available


  19. WASSERBAUER M, Hlava S, Drabek J, Stovicek J, et al
    Adalimumab biosimilars in the therapy of Crohn s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
    PLoS One. 2022;17:e0271299.
    PubMed     Abstract available


  20. KANG YH, Tucker SA, Quevedo SF, Inal A, et al
    Metabolic analyses reveal dysregulated NAD+ metabolism and altered mitochondrial state in ulcerative colitis.
    PLoS One. 2022;17:e0273080.
    PubMed     Abstract available


  21. WASSERBAUER M, Hlava S, Trojanek M, Stovicek J, et al
    Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.
    PLoS One. 2022;17:e0273612.
    PubMed     Abstract available


  22. BAMBO GM, Shiferaw E, Melku M
    A mean platelet volume in inflammatory bowel disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0273417.
    PubMed     Abstract available


  23. KERN I, Schoffer O, Richter T, Kiess W, et al
    Current and projected incidence trends of pediatric-onset inflammatory bowel disease in Germany based on the Saxon Pediatric IBD Registry 2000-2014 -a 15-year evaluation of trends.
    PLoS One. 2022;17:e0274117.
    PubMed     Abstract available


  24. BIANCHI R, Mamadou-Pathe B, von Kanel R, Roth R, et al
    Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients.
    PLoS One. 2022;17:e0274665.
    PubMed     Abstract available


  25. ELAMIR A, Shaker O, Kamal M, Khalefa A, et al
    Expression profile of serum LncRNA THRIL and MiR-125b in inflammatory bowel disease.
    PLoS One. 2022;17:e0275267.
    PubMed     Abstract available


  26. COLLIER AJ, Gomez DE, Monteith G, Plattner BL, et al
    Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study.
    PLoS One. 2022;17:e0276295.
    PubMed     Abstract available


  27. DOTTI I, Mayorgas A, Salas A
    Generation of human colon organoids from healthy and inflammatory bowel disease mucosa.
    PLoS One. 2022;17:e0276195.
    PubMed     Abstract available


  28. THOMAS S, Mercogliano G, Prendergast GC
    Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment.
    PLoS One. 2022;17:e0276910.
    PubMed     Abstract available


  29. SAHIN M, Erdogan KE, Tekingunduz E
    Correlation between the tissue ghrelin presence, disease activity and laboratory parameters in ulcerative colitis patients; immunohistochemical study.
    PLoS One. 2022;17:e0276065.
    PubMed     Abstract available


    January 2021
  30. KERN I, Schoffer O, Kiess W, Henker J, et al
    Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry.
    PLoS One. 2021;16:e0243774.
    PubMed     Abstract available


  31. KONSTANTINIDIS AO, Adamama-Moraitou KK, Pardali D, Dovas CI, et al
    Colonic mucosal and cytobrush sample cytokine mRNA expression in canine inflammatory bowel disease and their correlation with disease activity, endoscopic and histopathologic score.
    PLoS One. 2021;16:e0245713.
    PubMed     Abstract available


  32. NAFTALI T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, et al
    Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
    PLoS One. 2021;16:e0246871.
    PubMed     Abstract available


  33. REVILLA L, Mayorgas A, Corraliza AM, Masamunt MC, et al
    Multi-omic modelling of inflammatory bowel disease with regularized canonical correlation analysis.
    PLoS One. 2021;16:e0246367.
    PubMed     Abstract available


  34. DING ZH, Xu XP, Wang TR, Liang X, et al
    The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study.
    PLoS One. 2021;16:e0248427.
    PubMed     Abstract available


  35. RANA T, Korolkova OY, Rachakonda G, Williams AD, et al
    Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.
    PLoS One. 2021;16:e0246393.
    PubMed     Abstract available


  36. ARKTEG CB, Wergeland Sorbye S, Buhl Riis L, Dalen SM, et al
    Real-life evaluation of histologic scores for Ulcerative Colitis in remission.
    PLoS One. 2021;16:e0248224.
    PubMed     Abstract available


  37. TAMAN H, Fenton CG, Anderssen E, Florholmen J, et al
    DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.
    PLoS One. 2021;16:e0248905.
    PubMed     Abstract available


  38. FURUSE M, Hosomi S, Nishida Y, Itani S, et al
    The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
    PLoS One. 2021;16:e0250597.
    PubMed     Abstract available


  39. XU F, Park S, Liu Y, Greenlund KJ, et al
    Dietary intake patterns among adults with inflammatory bowel disease in the United States, 2015.
    PLoS One. 2021;16:e0250441.
    PubMed     Abstract available


  40. ISHIDA N, Higuchi T, Miyazu T, Tamura S, et al
    Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
    PLoS One. 2021;16:e0250658.
    PubMed     Abstract available


  41. BUSINGYE D, Pollack A, Chidwick K
    Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.
    PLoS One. 2021;16:e0252458.
    PubMed     Abstract available


  42. TREFZER R, Elpeleg O, Gabrusskaya T, Stepensky P, et al
    Characterization of a L136P mutation in Formin-like 2 (FMNL2) from a patient with chronic inflammatory bowel disease.
    PLoS One. 2021;16:e0252428.
    PubMed     Abstract available


  43. YEN HH, Su PY, Huang SP, Wu L, et al
    Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    PLoS One. 2021;16:e0252286.
    PubMed     Abstract available


  44. SMITH SCL, Banbury C, Zardo D, Cannatelli R, et al
    Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0252210.
    PubMed     Abstract available


  45. CAPITANO ML, Jaiswal A, Broxmeyer HE, Pride Y, et al
    A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease.
    PLoS One. 2021;16:e0252805.
    PubMed     Abstract available


  46. KATO M, Sugimoto K, Ikeya K, Takano R, et al
    Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0254548.
    PubMed     Abstract available


  47. ORFEI M, Gasparetto M, Hensel KO, Zellweger F, et al
    Guidance on the interpretation of faecal calprotectin levels in children.
    PLoS One. 2021;16:e0246091.
    PubMed     Abstract available


  48. MADARAME A, Fukuzawa M, Yamauchi Y, Kono S, et al
    Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.
    PLoS One. 2021;16:e0255620.
    PubMed     Abstract available


  49. LEE JM, Jang JH, Ryu JH, Yoo J, et al
    A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease.
    PLoS One. 2021;16:e0255974.
    PubMed     Abstract available


  50. GAN RW, Sun D, Tatro AR, Cohen-Mekelburg S, et al
    Replicating prediction algorithms for hospitalization and corticosteroid use in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0257520.
    PubMed     Abstract available


  51. ZHANG L, Wu YB, Dai YK, Liu Q, et al
    Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis.
    PLoS One. 2021;16:e0257599.
    PubMed     Abstract available


  52. KARMI N, Bangma A, Spekhorst LM, van Dullemen HM, et al
    Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFalpha therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0256860.
    PubMed     Abstract available


  53. AL-SADI R, Engers J, Haque M, King S, et al
    Matrix Metalloproteinase-9 (MMP-9) induced disruption of intestinal epithelial tight junction barrier is mediated by NF-kappaB activation.
    PLoS One. 2021;16:e0249544.
    PubMed     Abstract available


  54. CREEMERS RH, Rezazadeh Ardabili A, Jonkers DM, Leers MPG, et al
    Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
    PLoS One. 2021;16:e0258271.
    PubMed     Abstract available


  55. TAO F, Xing X, Wu J, Jiang R, et al
    Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice.
    PLoS One. 2021;16:e0248482.
    PubMed     Abstract available


  56. MEI Z, Feng Q, Du P, Li B, et al
    Surgical treatment for cryptoglandular and Crohn's perianal fistulas: Protocol of an umbrella review.
    PLoS One. 2021;16:e0251460.
    PubMed     Abstract available


  57. MORAN MM, Wessman P, Rolfson O, Bohl DD, et al
    The risk of revision following total hip arthroplasty in patients with inflammatory bowel disease, a registry based study.
    PLoS One. 2021;16:e0257310.
    PubMed     Abstract available


  58. BIN MASUD S, Jenkins C, Hussey E, Elkin-Frankston S, et al
    Utilizing machine learning with knockoff filtering to extract significant metabolites in Crohn's disease with a publicly available untargeted metabolomics dataset.
    PLoS One. 2021;16:e0255240.
    PubMed     Abstract available


  59. MIYAZAKI C, Katsumasa N, Huang KC, Liu YF, et al
    Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
    PLoS One. 2021;16:e0254807.
    PubMed     Abstract available


  60. WILSON PA, Santos Franco S, He L, Galwey NW, et al
    Transcriptomic effects of rs4845604, an IBD and allergy-associated RORC variant, in stimulated ex vivo CD4+ T cells.
    PLoS One. 2021;16:e0258316.
    PubMed     Abstract available


  61. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available


  62. PARK HT, Park WB, Kim S, Lim JS, et al
    Revealing immune responses in the Mycobacterium avium subsp. paratuberculosis-infected THP-1 cells using single cell RNA-sequencing.
    PLoS One. 2021;16:e0254194.
    PubMed     Abstract available


  63. WANG J, Bleich RM, Zarmer S, Zhang S, et al
    Long-read sequencing to interrogate strain-level variation among adherent-invasive Escherichia coli isolated from human intestinal tissue.
    PLoS One. 2021;16:e0259141.
    PubMed     Abstract available


  64. MORIKUBO H, Kobayashi T, Fukuda T, Nagahama T, et al
    Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database.
    PLoS One. 2021;16:e0258537.
    PubMed     Abstract available


  65. IRAK K, Bayram M, Cifci S, Sener G, et al
    Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease.
    PLoS One. 2021;16:e0260034.
    PubMed     Abstract available


  66. KHAN IA, Nayak B, Markandey M, Bajaj A, et al
    Differential prevalence of pathobionts and host gene polymorphisms in chronic inflammatory intestinal diseases: Crohn's disease and intestinal tuberculosis.
    PLoS One. 2021;16:e0256098.
    PubMed     Abstract available


    January 2020
  67. CAI B, Zhou MH, Huang HL, Zhou AC, et al
    Protective effects of citrulline supplementation in ulcerative colitis rats.
    PLoS One. 2020;15:e0240883.
    PubMed     Abstract available


  68. ALLAIS L, Verschuere S, Maes T, De Smet R, et al
    Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn's disease.
    PLoS One. 2020;15:e0236657.
    PubMed     Abstract available


  69. NISHIDA Y, Hosomi S, Yamagami H, Fujimoto K, et al
    Novel prognostic biomarkers of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: Neutrophil-to-lymphocyte ratio.
    PLoS One. 2020;15:e0241322.
    PubMed     Abstract available


  70. UCHIYAMA K, Takami S, Suzuki H, Umeki K, et al
    Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.
    PLoS One. 2020;15:e0241337.
    PubMed     Abstract available


  71. HOFFMANN P, Behnisch R, Gsenger J, Schnitzler P, et al
    Hepatitis E seroprevalence in a German cohort of patients with inflammatory bowel diseases.
    PLoS One. 2020;15:e0239825.
    PubMed     Abstract available


  72. LIMSRIVILAI J, Lee CK, Prueksapanich P, Harinwan K, et al
    Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn's disease: A multicenter study from Asia.
    PLoS One. 2020;15:e0242879.
    PubMed     Abstract available


  73. DOMENIS R, Marino M, Cifu A, Scardino G, et al
    Circulating exosomes express alpha4beta7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    PLoS One. 2020;15:e0242342.
    PubMed     Abstract available


  74. LI LN, Liu Y, Zhang HC, Wu T, et al
    Helicobacter pylori infection reduces TAMs infiltration in a mouse model of AOM/DSS induced colitis-associated cancer.
    PLoS One. 2020;15:e0241840.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: